Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

ObjectiveMacrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS. Many cases of MAS are medically refractory to traditional doses of b...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Mikhail M. Kostik, Eugenia A. Isupova, Konstantin Belozerov, Tatyana S. Likhacheva, Evgeny N. Suspitsin, Rinat Raupov, Vera V. Masalova, Irina A. Chikova, Margarita F. Dubko, Olga V. Kalashnikova, Vyacheslav G. Chasnyk, Randy Q. Cron
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2022-07-01
Ráidu:	Frontiers in Pediatrics
Fáttát:	canakinumab interleukin-1 macrophage activation syndrome monoclonal antibody dosing systemic juvenile idiopathic arthritis
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fped.2022.894846/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!